Recent approaches targeting beta-amyloid for therapeutic intervention of Alzheimer's disease

Recent Patents on CNS Drug Discovery

Volumn 6, Issue 3, 2011, Pages 222-233

  Cho, Jung Eun ^a   Kim, Jin Ryoun ^a  

^a POLYTECHNIC UNIVERSITY   (United States)

Author keywords

Aggregation; Alpha synuclein; Alzheimer's disease; Amyloid; Antibody; Beta amyloid; Tau

Indexed keywords

ALPHA SYNUCLEIN; ALPHA SYNUCLEIN ANTIBODY; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; FLURBIPROFEN; GAMMA SECRETASE INHIBITOR; HOMOTAURINE; IMATINIB; INOSITOL; INOSITOL DERIVATIVE; INSULIN; METHYLENE BLUE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3D6; NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDOMIMETIC AGENT; PROTEIN ANTIBODY; SCYLLOINOSITOL; SEMAGACESTAT; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SOLANEZUMAB; SOMATOMEDIN; SYNTHETIC AMYLOID BETA PROTEIN; SYNTHETIC PEPTIDE; THIAZINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ALZHEIMER DISEASE; DERIVATIVE; ANTIGEN BINDING; BINDING AFFINITY; BLOOD BRAIN BARRIER; CELL THERAPY; CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; HUMAN; IMMUNOTHERAPY; MENINGOENCEPHALITIS; NEUROPATHOLOGY; NONHUMAN; OLIGOMERIZATION; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; BRAIN; HUMANS; TAU PROTEINS;

EID: 80052234053     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488911796958002     Document Type: Review

References (237)

1. Dobson CM. Protein folding and misfolding. Nature 2003; 426: 884-890.
2. Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 2010; 9: 387-398.
3. Aguzzi A, O'Connor T. Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat Rev Drug Discov 2010; 9: 237-248.
4. Bolognesi ML, Matera R, Minarini A, Rosini M, Melchiorre C. Alzheimer's disease: new approaches to drug discovery. Curr Opin Chem Biol 2009; 13: 303-308.
5. Walsh DM, Selkoe DJ. A beta oligomers - a decade of discovery. J Neurochem 2007; 101: 1172-1184.
6. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid betapeptide. Nat Rev Mol Cell Biol 2007; 8: 101-112.
7. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 2007; 8: 499-509.
8. Ross CA, Poirier MA. Opinion: What is the role of protein aggregation in neurodegeneration? Nat Rev Mol Cell Biol 2005; 6: 891-898.
9. Alzheimer's Association. Alzheimer's Facts and Figures. Available at: http://www.alz.org/alzheimers_disease_facts_figures.asp. (Accessed on: July 20, 2011).
10. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987; 325: 733-736.
11. Walker ES, Martinez M, Brunkan AL, Goate A. Presenilin 2 familial Alzheimer's disease mutations result in partial loss of function and dramatic changes in Abeta 42/40 ratios. J Neurochem 2005; 92: 294-301.
12. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 2004; 430: 631-639.
13. Wolfe MS. The gamma-secretase complex: membrane-embedded proteolytic ensemble. Biochemistry 2006; 45: 7931-7939.
14. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349: 704-706.
15. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995; 375: 754-760.
16. Selkoe DJ. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol 2004; 6: 1054-1061.
17. Bertram L, Tanzi RE. The genetic epidemiology of neurodegenerative disease. J Clin Invest 2005; 115: 1449-1457.
18. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-923.
19. Ittner LM, Gotz J. Amyloid-beta and tau-a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 2011; 12: 65-72.
20. Walsh DM, Selkoe DJ. A beta oligomers - a decade of discovery. J Neurochem 2007; 101: 1172-1184.
21. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300: 486-489.
22. Lansbury PT, Lashuel HA. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 2006; 443: 774-779.
23. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 2007; 8: 499-509.
24. Finder VH, Glockshuber R. Amyloid-beta aggregation. Neurodegener Dis 2007; 4: 13-27.
25. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005; 8: 79-84.
26. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006; 440: 352-357.
27. Ittner LM, Gotz J. Amyloid-beta and tau--a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 2011; 12: 65-72.
28. Martin L, Latypova X, Terro F. Post-translational modifications of tau protein: implications for Alzheimer's disease. Neurochem Int 2011; 58: 458-471.
29. Martin L, Latypova X, Terro F. Post-translational modifications of tau protein: implications for Alzheimer's disease. Neurochem Int 2011; 58: 458-471.
30. Iqbal K, Liu F, Gong CX, Grundke-Iqbal I. Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res 2010; 7: 656-664.
31. Drewes G, Ebneth A, Preuss U, Mandelkow EM, Mandelkow E. MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell 1997; 89: 297-308.
32. Noble W, Olm V, Takata K, Casey E, Mary O, Meyerson J, et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 2003; 38: 555-565.
33. Gong CX, Grundke-Iqbal I, Iqbal K. Dephosphorylation of Alzheimer's disease abnormally phosphorylated tau by protein phosphatase-2A. Neuroscience 1994; 61: 765-772.
34. Yoshida H, Ihara Y. Tau in paired helical filaments is functionally distinct from fetal tau: assembly incompetence of paired helical filament-tau. J Neurochem 1993; 61: 1183-1186.
35. Bramblett GT, Goedert M, Jakes R, Merrick SE, Trojanowski JQ, Lee VM. Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron 1993; 10: 1089-1099.
36. Gotz J, Probst A, Spillantini MG, Schafer T, Jakes R, Burki K, et al. Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J 1995; 14: 1304-1313.
37. Alonso A, Zaidi T, Novak M, Grundke-Iqbal I, Iqbal K. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci U S A 2001; 98: 6923-6928.
38. Gotz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 2001; 293: 1491-1495.
39. von Bergen M, Friedhoff P, Biernat J, Heberle J, Mandelkow EM, Mandelkow E. Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. Proc Natl Acad Sci U S A 2000; 97: 5129-5134.
40. Liu F, Li B, Tung EJ, Grundke-Iqbal I, Iqbal K, Gong CX. Sitespecific effects of tau phosphorylation on its microtubule assembly activity and self-aggregation. Eur J Neurosci 2007; 26: 3429-3436.
41. Wischik CM, Edwards PC, Lai RY, Gertz HN, Xuereb JH, Paykel ES, et al. Quantitative analysis of tau protein in paired helical filament preparations: implications for the role of tau protein phosphorylation in PHF assembly in Alzheimer's disease. Neurobiol Aging 1995; 16: 409-417; discussion 418-431.
42. Peterson DW, Zhou H, Dahlquist FW, Lew J. A soluble oligomer of tau associated with fiber formation analyzed by NMR. Biochemistry 2008; 47: 7393-7404.
43. Fischer D, Mukrasch MD, Biernat J, Bibow S, Blackledge M, Griesinger C, et al. Conformational changes specific for pseudophosphorylation at serine 262 selectively impair binding of tau to microtubules. Biochemistry 2009; 48: 10047-10055.
44. Berriman J, Serpell LC, Oberg KA, Fink AL, Goedert M, Crowther RA. Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-beta structure. Proc Natl Acad Sci U S A 2003; 100: 9034-9038.
45. Steinhilb ML, Dias-Santagata D, Fulga TA, Felch DL, Feany MB. Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. Mol Biol Cell 2007; 18: 5060-5068.
46. Feuillette S, Miguel L, Frebourg T, Campion D, Lecourtois M. Drosophila models of human tauopathies indicate that Tau protein toxicity in vivo is mediated by soluble cytosolic phosphorylated forms of the protein. J Neurochem 2010; 113: 895-903.
47. Ittner LM, Ke YD, Gotz J. Phosphorylated Tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease. J Biol Chem 2009; 284: 20909-20916.
48. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005; 309: 476-481.
49. Bulic B, Pickhardt M, Schmidt B, Mandelkow EM, Waldmann H, Mandelkow E. Development of tau aggregation inhibitors for Alzheimer's disease. Angew Chem Int Ed Engl 2009; 48: 1740-1752.
50. Wang YP, Biernat J, Pickhardt M, Mandelkow E, Mandelkow EM. Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. Proc Natl Acad Sci U S A 2007; 104: 10252-10257.
51. Nie CL, Wang XS, Liu Y, Perrett S, He RQ. Amyloid-like aggregates of neuronal tau induced by formaldehyde promote apoptosis of neuronal cells. BMC Neurosci 2007; 8: 9.
52. King ME, Kan HM, Baas PW, Erisir A, Glabe CG, Bloom GS. Tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid. J Cell Biol 2006; 175: 541-546.
53. Park SY, Ferreira A. The generation of a 17 kDa neurotoxic fragment: an alternative mechanism by which tau mediates betaamyloid-induced neurodegeneration. J Neurosci 2005; 25: 5365-5375.
54. Small SA, Duff K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 2008; 60: 534-542.
55. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007; 316: 750-754.
56. Tseng BP, Green KN, Chan JL, Blurton-Jones M, LaFerla FM. Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol Aging 2008; 29: 1607-1618.
57. Thal DR, Holzer M, Rub U, Waldmann G, Gunzel S, Zedlick D, et al. Alzheimer-related tau-pathology in the perforant path target zone and in the hippocampal stratum oriens and radiatum correlates with onset and degree of dementia. Exp Neurol 2000; 163: 98-110.
58. Ueda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M, et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A 1993; 90: 11282-11286.
59. Jensen PH, Hojrup P, Hager H, Nielsen MS, Jacobsen L, Olesen OF, et al. Binding of Abeta to alpha- and beta-synucleins: identification of segments in alpha-synuclein/NAC precursor that bind Abeta and NAC. Biochem J 1997; 323 (Pt 2): 539-546.
60. Ono K, Hirohata M, Yamada M. Alpha-synuclein assembly as a therapeutic target of Parkinson's disease and related disorders. Curr Pharm Des 2008; 14: 3247-3266.
61. Uversky VN. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J Neurochem 2007; 103: 17-37.
62. Fink AL. The aggregation and fibrillation of alpha-synuclein. Acc Chem Res 2006; 39: 628-634.
63. Vilar M, Chou HT, Luhrs T, Maji SK, Riek-Loher D, Verel R, et al. The fold of alpha-synuclein fibrils. Proc Natl Acad Sci U S A 2008; 105: 8637-8642.
64. Heise H, Hoyer W, Becker S, Andronesi OC, Riedel D, Baldus M. Molecular-level secondary structure, polymorphism, and dynamics of full-length alpha-synuclein fibrils studied by solid-state NMR. Proc Natl Acad Sci U S A 2005; 102: 15871-15876.
65. Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, et al. In vivo demonstration that {alpha}-synuclein oligomers are toxic. Proc Natl Acad Sci U S A 2011; 108: 4194-4199.
66. Iwai A, Yoshimoto M, Masliah E, Saitoh T. Non-A beta component of Alzheimer's disease amyloid (NAC) is amyloidogenic. Biochemistry 1995; 34: 10139-10145.
67. Giasson BI, Murray IV, Trojanowski JQ, Lee VM. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem 2001; 276: 2380-2386.
68. Giehm L, Svergun DI, Otzen DE, Vestergaard B. Low-resolution structure of a vesicle disrupting α-synuclein oligomer that accumulates during fibrillation. Proc Natl Acad Sci U S A 2011; 108: 3246-3251.
69. van Rooijen BD, Claessens MM, Subramaniam V. Membrane Permeabilization by Oligomeric alpha-Synuclein: In Search of the Mechanism. PLoS One 2010; 5: e14292.
70. Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, Kessler JC, et al. Vesicle permeabilization by protofibrillar alphasynuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 2001; 40: 7812-7819.
71. Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, et al. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci 2007; 27: 9220-9232.
72. Lee HJ, Kim C, Lee SJ. Alpha-synuclein stimulation of astrocytes: Potential role for neuroinflammation and neuroprotection. Oxid Med Cell Longev 2010; 3: 283-287.
73. Hinault MP, Cuendet AF, Mattoo RU, Mensi M, Dietler G, Lashuel HA, et al. Stable alpha-synuclein oligomers strongly inhibit chaperone activity of the Hsp70 system by weak interactions with J-domain co-chaperones. J Biol Chem 2010; 285: 38173-38182.
74. Hansen RA, Gartlehner G, Lohr KN, Kaufer DI. Functional outcomes of drug treatment in Alzheimer's disease: A systematic review and meta-analysis. Drugs Aging 2007; 24: 155-167.
75. Chauhan V, Chauhan A. Oxidative stress in Alzheimer's disease. Pathophysiology 2006; 13: 195-208.
76. Porat Y, Abramowitz A, Gazit E. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des 2006; 67: 27-37.
77. Barten DM, Albright CF. Therapeutic strategies for Alzheimer's disease. Mol Neurobiol 2008; 37: 171-186.
78. Pangalos MN, Jacobsen SJ, Reinhart PH. Disease modifying strategies for the treatment of Alzheimer's disease targeted at modulating levels of the beta-amyloid peptide. Biochem Soc Trans 2005; 33: 553-558.
79. Hawkes CA, McLaurin J. Immunotherapy as treatment for Alzheimer's disease. Expert Rev Neurother 2007; 7: 1535-1548.
80. Amijee H, Madine J, Middleton DA, Doig AJ. Inhibitors of protein aggregation and toxicity. Biochem Soc Trans 2009; 37: 692-696.
81. Hamaguchi T, Ono K, Yamada M. Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer's disease. Cell Mol Life Sci 2006; 63: 1538-1552.
82. Hirohata M, Ono K, Yamada M. Non-steroidal anti-inflammatory drugs as anti-amyloidogenic compounds. Curr Pharm Des 2008; 14: 3280-3294.
83. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999; 286: 735-741.
84. Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, et al. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 1999; 402: 533-537.
85. Sankaranarayanan S, Price EA, Wu G, Crouthamel MC, Shi XP, Tugusheva K, et al. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1. J Pharmacol Exp Ther 2008; 324: 957-969.
86. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 2001; 4: 231-232.
87. Ohno M, Sametsky EA, Younkin LH, Oakley H, Younkin SG, Citron M, et al. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron 2004; 41: 27-33.
88. Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD, et al. Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci 2006; 9: 1520-1505.
89. McConlogue L, Buttini M, Anderson JP, Brigham EF, Chen KS, Freedman SB, et al. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice. J Biol Chem 2007; 282: 26326-26334.
90. Leung D, Abbenante G, Fairlie DP. Protease inhibitors: current status and future prospects. J Med Chem 2000; 43: 305-341.
91. Ghosh AK, Kumaragurubaran N, Hong L, Koelsh G, Tang J. Memapsin 2 (beta-secretase) inhibitors: drug development. Curr Alzheimer Res 2008; 5: 121-131.
92. Durham TB, Shepherd TA. Progress toward the discovery and development of efficacious BACE inhibitors. Curr Opin Drug Discov Devel 2006; 9: 776-791.
93. Neugroschl J, Sano M. An update on treatment and prevention strategies for Alzheimer's disease. Curr Neurol Neurosci Rep 2009; 9: 368-376.
94. Willem M, Dewachter I, Smyth N, Van Dooren T, Borghgraef P, Haass C, et al. Beta-site amyloid precursor protein cleaving enzyme 1 increases amyloid deposition in brain parenchyma but reduces cerebrovascular amyloid angiopathy in aging BACE x APP[V717I] double-transgenic mice. Am J Pathol 2004; 165: 1621-1631.
95. Lichtenthaler SF. Alpha-secretase in Alzheimer's disease: molecular identity, regulation and therapeutic potential. J Neurochem 2011; 116: 10-21.
96. Hock C, Maddalena A, Raschig A, Muller-Spahn F, Eschweiler G, Hager K, et al. Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. Amyloid 2003; 10: 1-6.
97. Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY, et al. Functional gamma-secretase inhibitors reduce betaamyloid peptide levels in brain. J Neurochem 2001; 76: 173-181.
98. Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, Tariot P, et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 2006; 66: 602-604.
99. Best JD, Jay MT, Otu F, Ma J, Nadin A, Ellis S, et al. Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-ox o-6,7-dihydro-5Hdibenzo[ b,d]azepin-7-yl]-L-alaninamide]. J Pharmacol Exp Ther 2005; 313: 902-908.
100. Iwatsubo, T., Kodama, T., Hamakubo, T., Tomita, T., Hayashi, I., Urano, Y., Iwanari, H., Ohkuchi, M. Therapeutic agents for Alzheimer's disease and cancer. US20110165179 (2011).
101. Lovell, M., Lynn, B. Treatment of MCI and Alzheimer's disease. US20100292281 (2010).
102. De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998; 391: 387-390.
103. De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 1999; 398: 518-522.
104. Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004; 279: 12876-12882.
105. Milano J, McKay J, Dagenais C, Foster-Brown L, Pognan F, Gadient R, et al. Modulation of notch processing by gammasecretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci 2004; 82: 341-358.
106. Wong PC, Zheng H, Chen H, Becher MW, Sirinathsinghji DJ, Trumbauer ME, et al. Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm. Nature 1997; 387: 288-292.
107. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, et al. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 2008; 65: 1031-1038.
108. Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, et al. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol 2009; 66: 48-54.
109. Martone RL, Zhou H, Atchison K, Comery T, Xu JZ, Huang X, et al. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Ther 2009; 331: 598-608.
110. Basi GS, Hemphill S, Brigham EF, Liao A, Aubele DL, Baker J, et al. Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease. Alzheimers Res Ther 2010; 2: 36.
111. Imbimbo BP, Giardina GA. Gamma-Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease: Disappointments and Hopes. Curr Top Med Chem 2011; 11: 1555-1570.
112. Imbimbo BP, Panza F, Frisardi V, Solfrizzi V, D'Onofrio G, Logroscino G, et al. Therapeutic intervention for Alzheimer's disease with gamma-secretase inhibitors: still a viable option? Expert Opin Investig Drugs 2011; 20: 325-341.
113. Imbimbo BP, Peretto I. Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer's disease. Curr Opin Investig Drugs 2009; 10: 721-730.
114. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001; 414: 212-216.
115. Jarrett JT, Berger EP, Lansbury PT, Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993; 32: 4693-4697.
116. Kukar TL, Ladd TB, Bann MA, Fraering PC, Narlawar R, Maharvi GM, et al. Substrate-targeting gamma-secretase modulators. Nature 2008; 453: 925-929.
117. Fraering PC, Ye W, LaVoie MJ, Ostaszewski BL, Selkoe DJ, Wolfe MS. gamma-Secretase substrate selectivity can be modulated directly via interaction with a nucleotide-binding site. J Biol Chem 2005; 280: 41987-41996.
118. Leuchtenberger S, Beher D, Weggen S. Selective modulation of Abeta42 production in Alzheimer's disease: non-steroidal anti-inflammatory drugs and beyond. Curr Pharm Des 2006; 12: 4337-4355.
119. Wilcock GK, Black SE, Balch AH, Amato DA, Beelen AP, Schneider LS, et al. Safety and efficacy of tarenflurbil in subjects with mild Alzheimer's disease: Results from an 18-month international multi-center phase 3 trial. Alzheimers Dement 2009; 5: P86.
120. Galasko DR, Graff-Radford N, May S, Hendrix S, Cottrell BA, Sagi SA, et al. Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis Assoc Disord 2007; 21: 292-299.
121. Cheng, S., Comer, D., Mao, L., Balow, G., Playnet, D. Compounds and uses thereof in modulating amyloid beta. US7781442 (2010).
122. Kounnas MZ, Danks AM, Cheng S, Tyree C, Ackerman E, Zhang X, et al. Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron 2010; 67: 769-780.
123. Netzer WJ, Dou F, Cai D, Veach D, Jean S, Li Y, et al. Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc Natl Acad Sci U S A 2003; 100: 12444-12449.
124. He G, Luo W, Li P, Remmers C, Netzer WJ, Hendrick J, et al. Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature 2010; 467: 95-98.
125. Greengard, P., Lou, W., He, G., Li, P., Wennogle, L. Novel Regulatory proteins and inhibitors. WO2011016861 (2011).
126. Bentwich, I., Amir, A. Bioinformatically detectable group of novel regulatory oligonucleotide and uses thereof. US7888497 (2011).
127. Willnow, T. Method of upregulating SorLA for the treatment of Alzheimer's disease. US20110104165 (2011).
128. Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, et al. BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci 2005; 25: 11693-11709.
129. Kim DY, Carey BW, Wang H, Ingano LA, Binshtok AM, Wertz MH, et al. BACE1 regulates voltage-gated sodium channels and neuronal activity. Nat Cell Biol 2007; 9: 755-764.
130. Kuhn PH, Marjaux E, Imhof A, De Strooper B, Haass C, Lichtenthaler SF. Regulated intramembrane proteolysis of the interleukin-1 receptor II by alpha-, beta-, and gamma-secretase. J Biol Chem 2007; 282: 11982-11995.
131. Wong HK, Sakurai T, Oyama F, Kaneko K, Wada K, Miyazaki H, et al. beta Subunits of voltage-gated sodium channels are novel substrates of beta-site amyloid precursor protein-cleaving enzyme (BACE1) and gamma-secretase. J Biol Chem 2005; 280: 23009-23017.
132. Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, et al. Control of peripheral nerve myelination by the betasecretase BACE1. Science 2006; 314: 664-666.
133. Esteban JA. Living with the enemy: a physiological role for the beta-amyloid peptide. Trends Neurosci 2004; 27: 1-3.
134. Plant LD, Boyle JP, Smith IF, Peers C, Pearson HA. The production of amyloid beta peptide is a critical requirement for the viability of central neurons. J Neurosci 2003; 23: 5531-5535.
135. Amijee H, Scopes DI. The quest for small molecules as amyloid inhibiting therapies for Alzheimer's disease. J Alzheimers Dis 2009; 17: 33-47.
136. Apostol BL, Kazantsev A, Raffioni S, Illes K, Pallos J, Bodai L, et al. A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proc Natl Acad Sci U S A 2003; 100: 5950-5955.
137. Austen BM, Paleologou KE, Ali SA, Qureshi MM, Allsop D, El-Agnaf OM. Designing peptide inhibitors for oligomerization and toxicity of Alzheimer's beta-amyloid peptide. Biochemistry 2008; 47: 1984-1992.
138. Baine M, Georgie DS, Shiferraw EZ, Nguyen TP, Nogaj LA, Moffet DA. Inhibition of Abeta42 aggregation using peptides selected from combinatorial libraries. J Pept Sci 2009; 15: 499-503.
139. Snow, A., Nguyen, B., Castillo, G., Sanders, V., Lake, T., Larsen, L., Weavers, R. T., Lorimer, S. Larsen, D. Coffen, D. L. Coffen, C. Compounds, compositions and methods for the treatment of amyloid disease and synucleinopathies such as Alzheimer's disease, type 2 diabetes and Parkinson's disease. US20110172239 (2011).
140. Hawkes CA, Ng V, McLaurin J. Small molecule inhibitors of Abeta-aggregation and neurotoxicity. Drug Dev Res 2009; 70: 111-124.
141. Findeis MA, Phillips K, Olsen G, Self C. Modulator of b-amyloid peptide aggregation. US 7803774 (2010).
142. Tjernberg LO, Naslund J, Lindqvist F, Johansson J, Karlstrom AR, Thyberg J, et al. Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J Biol Chem 1996; 271: 8545-8548.
143. Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castano EM, Frangione B. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med 1998; 4: 822-826.
144. Liu R, McAllister C, Lyubchenko Y, Sierks MR. Residues 17-20 and 30-35 of beta-amyloid play critical roles in aggregation. J Neurosci Res 2004; 75: 162-171.
145. Pallitto MM, Ghanta J, Heinzelman P, Kiessling LL, Murphy RM. Recognition sequence design for peptidyl modulators of betaamyloid aggregation and toxicity. Biochemistry 1999; 38: 3570-3578.
146. Doig AJ. Peptide inhibitors of beta-amyloid aggregation. Curr Opin Drug Discov Devel 2007; 10: 533-539.
147. Talaga P. Inhibitors of beta-amyloid aggregation: still an issue of structure and function? Drug Discov Today: Therapeutic Strategies 2004; 1: 7-12.
148. Aisen PS, Saumier D, Briand R, Laurin J, Gervais F, Tremblay P, et al. A Phase II study targeting amyloid-beta with 3APS in mildto-moderate Alzheimer disease. Neurology 2006; 67: 1757-1763.
149. Gervais F, Paquette J, Morissette C, Krzywkowski P, Yu M, Azzi M, et al. Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging 2007; 28: 537-547.
150. Dasilva KA, Shaw JE, McLaurin J. Amyloid-beta fibrillogenesis: structural insight and therapeutic intervention. Exp Neurol 2010; 223: 311-321.
151. Aisen, P., Mehran, M., Poole, R. Clinical data on Alzhemed after 12 months of treatment in patients with mild to moderate Alzheimer's disease. The 9th International Conference on Alzheimer's Disease and Related Disorders. Philadelphia, USA (2004).
152. De Felice FG, Vieira MN, Saraiva LM, Figueroa-Villar JD, Garcia-Abreu J, Liu R, et al. Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Abeta oligomerization. FASEB J 2004; 18: 1366-1372.
153. McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lambermon MH, Phinney AL, et al. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med 2006; 12: 801-808.
154. Gellermann GP, Byrnes H, Striebinger A, Ullrich K, Mueller R, Hillen H, et al. Abeta-globulomers are formed independently of the fibril pathway. Neurobiol Dis 2008; 30: 212-220.
155. Yu L, Edalji R, Harlan JE, Holzman TF, Lopez AP, Labkovsky B, et al. Structural characterization of a soluble amyloid beta-peptide oligomer. Biochemistry 2009; 48: 1870-1807.
156. Ahmed M, Davis J, Aucoin D, Sato T, Ahuja S, Aimoto S, et al. Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils. Nat Struct Mol Biol 2010; 17: 561-567.
157. Goldsbury C, Frey P, Olivieri V, Aebi U, Muller SA. Multiple assembly pathways underlie amyloid-beta fibril polymorphisms. J Mol Biol 2005; 352: 282-298.
158. Liu D, Xu Y, Feng Y, Liu H, Shen X, Chen K, et al. Inhibitor discovery targeting the intermediate structure of beta-amyloid peptide on the conformational transition pathway: implications in the aggregation mechanism of beta-amyloid peptide. Biochemistry 2006; 45: 10963-10972.
159. Sato T, Kienlen-Campard P, Ahmed M, Liu W, Li H, Elliott JI, et al. Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42. Biochemistry 2006; 45: 5503-5516.
160. Chen D, Martin ZS, Soto C, Schein CH. Computational selection of inhibitors of Abeta aggregation and neuronal toxicity. Bioorg Med Chem 2009; 17: 5189-5197.
161. Lashuel HA, Hartley DM, Balakhaneh D, Aggarwal A, Teichberg S, Callaway DJ. New class of inhibitors of amyloid-beta fibril formation. Implications for the mechanism of pathogenesis in Alzheimer's disease. J Biol Chem 2002; 277: 42881-4290.
162. Necula M, Kayed R, Milton S, Glabe CG. Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J Biol Chem 2007; 282: 10311-10324.
163. LeVine H, 3rd. Small molecule inhibitors of Abeta assembly. Amyloid 2007; 14: 185-197.
164. Findeis MA. Approaches to discovery and characterization of inhibitors of amyloid beta-peptide polymerization. Biochim Biophys Acta 2000; 1502: 76-84.
165. Stains CI, Mondal K, Ghosh I. Molecules that target beta-amyloid. ChemMedChem 2007; 2: 1674-1692.
166. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 2002; 5: 452-457.
167. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-diseaselike pathology in the PDAPP mouse. Nature 1999; 400: 173-177.
168. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000; 408: 982-985.
169. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000; 408: 979-982.
170. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid betapeptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6: 916-919.
171. Frenkel D, Katz O, Solomon B. Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration. Proc Natl Acad Sci U S A 2000; 97: 11455-1149.
172. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2001; 98: 8850-8855.
173. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64: 1553-1562.
174. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003; 38: 547-554.
175. Schenk, D. B. Humanized antibodies that recognize beta amyloid peptide. US7893214 (2011).
176. Basi, G., Saldanha, J., Bard, F. Humanized antibodies that recognize beta amyloid peptide. US 7871615 (2011).
177. Seubert P, Barbour R, Khan K, Motter R, Tang P, Kholodenko D, et al. Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse. Neurodegener Dis 2008; 5: 65-71.
178. Basi GS, Feinberg H, Oshidari F, Anderson J, Barbour R, Baker J, et al. Structural correlates of antibodies associated with acute reversal of amyloid beta-related behavioral deficits in a mouse model of Alzheimer disease. J Biol Chem 2010; 285: 3417-3427.
179. Dodel R, Hampel H, Depboylu C, Lin S, Gao F, Schock S, et al. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol 2002; 52: 253-256.
180. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, et al. Exacerbation of cerebral amyloid angiopathyassociated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 2005; 25: 629-636.
181. Thakker DR, Weatherspoon MR, Harrison J, Keene TE, Lane DS, Kaemmerer WF, et al. Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice. Proc Natl Acad Sci U S A 2009; 106: 4501-4506.
182. Fukuchi K, Accavitti-Loper MA, Kim HD, Tahara K, Cao Y, Lewis TL, et al. Amelioration of amyloid load by anti-Abeta single-chain antibody in Alzheimer mouse model. Biochem Biophys Res Commun 2006; 344: 79-86.
183. Zameer A, Kasturirangan S, Emadi S, Nimmagadda SV, Sierks MR. Anti-oligomeric Abeta single-chain variable domain antibody blocks Abeta-induced toxicity against human neuroblastoma cells. J Mol Biol 2008; 384: 917-928.
184. Robert R, Dolezal O, Waddington L, Hattarki MK, Cappai R, Masters CL, et al. Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers. Protein Eng Des Sel 2009; 22: 199-208.
185. Marin-Argany M, Rivera-Hernandez G, Marti J, Villegas S. An anti-Abeta (amyloid beta) single-chain variable fragment prevents amyloid fibril formation and cytotoxicity by withdrawing Abeta oligomers from the amyloid pathway. Biochem J 2011; 437: 25-34.
186. Cohen E, Paulsson JF, Blinder P, Burstyn-Cohen T, Du D, Estepa G, et al. Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell 2009; 139: 1157-1169.
187. Cohen, E., Dillin, A. Method of treating neurodegenerative disease. WO2010075511 (2010).
188. Leissring MA. Proteolytic degradation of the amyloid beta-protein: the forgotten side of Alzheimer's disease. Curr Alzheimer Res 2006; 3: 431-435.
189. Kim MJ, Chae SS, Koh YH, Lee SK, Jo SA. Glutamate carboxypeptidase II: an amyloid peptide-degrading enzyme with physiological function in the brain. FASEB J 2010; 24: 4491-4502.
190. Carson JA, Turner AJ. Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases? J Neurochem 2002; 81: 1-8.
191. Medeiros R, Baglietto-Vargas D, Laferla FM. The Role of Tau in Alzheimer's Disease and Related Disorders. CNS Neurosci Ther 2010
192. LaFerla FM. Pathways linking Abeta and tau pathologies. Biochem Soc Trans 2010; 38: 993-995.
193. Pickhardt M, Larbig G, Khlistunova I, Coksezen A, Meyer B, Mandelkow EM, et al. Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells. Biochemistry 2007; 46: 10016-10023.
194. van Eersel J, Ke YD, Liu X, Delerue F, Kril JJ, Gotz J, et al. Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. Proc Natl Acad Sci U S A 2010; 107: 13888-13893.
195. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A 2005; 102: 6990-6995.
196. Kosik KS, Shimura H. Phosphorylated tau and the neurodegenerative foldopathies. Biochim Biophys Acta 2005; 1739: 298-310.
197. Kelleher I, Garwood C, Hanger DP, Anderton BH, Noble W. Kinase activities increase during the development of tauopathy in htau mice. J Neurochem 2007; 103: 2256-2267.
198. Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A 1996; 93: 11213-11218.
199. Haase C, Stieler JT, Arendt T, Holzer M. Pseudophosphorylation of tau protein alters its ability for self-aggregation. J Neurochem 2004; 88: 1509-1520.
200. Wischik, C.M., Horsley, D., Rickard, J.E., Harrington, C.R. Materials and methods relating to protein aggregation in neurodegenerative disease. US7893054 (2011).
201. Wischik, C.M., Rickard, J.E., Harrington, C.R., Horsley, D., Storey, J.M.D., Marshall, C., Sinclair, J.P. Preparation of phenothiazine derivatives for treatment of tauopathy. WO 2007110630 (2007).
202. Wischik, CM, Bentham, P, Wischik, DJ, Seng, KM. Tau Aggregation Inhibitors (TAI) Therapy with Remembertm Arrests Disease Progression in Mild and Moderate Alzheimer's Disease over 50 Weeks. International Conference on Alzheimer's Disease. Chicago, USA (2008).
203. Feng BY, Toyama BH, Wille H, Colby DW, Collins SR, May BC, et al. Small-molecule aggregates inhibit amyloid polymerization. Nat Chem Biol 2008; 4: 197-9.
204. Bulic B, Pickhardt M, Mandelkow EM, Mandelkow E. Tau protein and tau aggregation inhibitors. Neuropharmacology 2010; 59: 276-289.
205. Jensen PH, Sorensen ES, Petersen TE, Gliemann J, Rasmussen LK. Residues in the synuclein consensus motif of the alpha-synuclein fragment, NAC, participate in transglutaminase-catalysed crosslinking to Alzheimer-disease amyloid beta A4 peptide. Biochem J 1995; 310 (Pt 1): 91-94.
206. Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT, Jr. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 1996; 35: 13709-13715.
207. Nath S, Meuvis J, Hendrix J, Carl SA, Engelborghs Y. Early aggregation steps in alpha-synuclein as measured by FCS and FRET: evidence for a contagious conformational change. Biophys J 2010; 98: 1302-1311.
208. Chilcote, T., Barbour, R. Antibodies to alpha-synuclein. US7910333 (2011).
209. Lindvall O, Kokaia Z. Stem cells in human neurodegenerative disorders--time for clinical translation? J Clin Invest 2010; 120: 29-40.
210. Sugaya K, Merchant S. How to approach Alzheimer's disease therapy using stem cell technologies. J Alzheimers Dis 2008; 15: 241-254.
211. Kihm, A.J., Gosiewska, A. Human Umbilical cord tissue cells as therapy for Alzheimer's disease. WO2010111663 (2010).
212. Urbaniak Hunter K, Yarbrough C, Ciacci J. Gene- and cell-based approaches for neurodegenerative disease. Adv Exp Med Biol 2010; 671: 117-130.
213. Flavell, R.A., Town, T.C. Targeting TGF-beta as a therapy for Alzheimer's disease US 20110136892 (2011).
214. Maxfield, F., Lobel, P. CLN2 treatment of Alzheimer's disease. US20110166074 (2011).
215. Tabner BJ, El-Agnaf OM, Turnbull S, German MJ, Paleologou KE, Hayashi Y, et al. Hydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer disease and familial British dementia. J Biol Chem 2005; 280: 35789-35792.
216. Barnham KJ, Ciccotosto GD, Tickler AK, Ali FE, Smith DG, Williamson NA, et al. Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation. J Biol Chem 2003; 278: 42959-42965.
217. Huang X, Atwood CS, Hartshorn MA, Multhaup G, Goldstein LE, Scarpa RC, et al. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 1999; 38: 7609-7616.
218. Opazo C, Huang X, Cherny RA, Moir RD, Roher AE, White AR, et al. Metalloenzyme-like activity of Alzheimer's disease betaamyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem 2002; 277: 40302-40308.
219. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. J Neurochem 2003; 87: 172-181.
220. Matsubara E, Bryant-Thomas T, Pacheco Quinto J, Henry TL, Poeggeler B, Herbert D, et al. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J Neurochem 2003; 85: 1101-1108.
221. Abdul HM, Calabrese V, Calvani M, Butterfield DA. Acetyl-Lcarnitine-induced up-regulation of heat shock proteins protects cortical neurons against amyloid-beta peptide 1-42-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. J Neurosci Res 2006; 84: 398-408.
222. Bush AI. Metal complexing agents as therapies for Alzheimer's disease. Neurobiol Aging 2002; 23: 1031-1038.
223. Kwon MO, Herrling P. List of drugs in development for neurodegenerative diseases. Update June 2006. Neurodegener Dis 2006; 3: 148-186.
224. Hindo SS, Mancino AM, Braymer JJ, Liu Y, Vivekanandan S, Ramamoorthy A, et al. Small molecule modulators of copperinduced Abeta aggregation. J Am Chem Soc 2009; 131: 16663-16665.
225. Leoutsakos JM, Muthen BO, Breitner JC, Lyketsos CG. Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Antiinflammatory Prevention Trial. Int J Geriatr Psychiatry 2011
226. Weinreb O, Mandel S, Bar-Am O, Yogev-Falach M, Avramovich-Tirosh Y, Amit T, et al. Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs. Neurotherapeutics 2009; 6: 163-174.
227. Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, et al. Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement 2011; 7: 402-411.
228. Saragovi HU, Hamel E, Di Polo A. A neurotrophic rationale for the therapy of neurodegenerative disorders. Curr Alzheimer Res 2009; 6: 419-423.
229. Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol 2009; 5: 311-322.
230. Schindowski K, Belarbi K, Buee L. Neurotrophic factors in Alzheimer's disease: role of axonal transport. Genes Brain Behav 2008; 7 Suppl 1: 43-56.
231. Rojo LE, Fernandez JA, Maccioni AA, Jimenez JM, Maccioni RB. Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch Med Res 2008; 39: 1-16.
232. Hoozemans JJ, Veerhuis R, Rozemuller JM, Eikelenboom P. Soothing the inflamed brain: effect of non-steroidal anti-inflammatory drugs on Alzheimer's disease pathology. CNS Neurol Disord Drug Targets 2011; 10: 57-67.
233. Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 2009; 457: 981-989.
234. Nikolaev, A., Tessier-Lavigne, M. DR6 antagonists and uses thereof in treating neurological disorders. US20100203044 (2010).
235. Hansen LA, Masliah E, Terry RD, Mirra SS. A neuropathological subset of Alzheimer's disease with concomitant Lewy body disease and spongiform change. Acta Neuropathol 1989; 78: 194-201.
236. Bolognesi ML, Banzi R, Bartolini M, Cavalli A, Tarozzi A, Andrisano V, et al. Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease. J Med Chem 2007; 50: 4882-4897.
237. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734-746.